SCHEMBL6416003

SCHEMBL6416003

O=C(O)c1cc(-c2ccc(C=NNc3nc4nonc4nc3Nc3ccc(Br)cc3)o2)ccc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 9/20 0.61
KMT2A Q03164 9/20 0.61
KDM4E B2RXH2 9/20 0.61
ALDH1A1 P00352 8/20 0.61
MAPT P10636 7/20 0.61
GAA P10253 7/20 0.61
HPGD P15428 2/20 0.61
ALOX12 P18054 1/20 0.61
NPSR1 Q6W5P4 1/20 0.61
NPC1 O15118 5/20 0.54
RAB9A P51151 5/20 0.54
POLB P06746 8/20 0.54
BIRC5 O15392 1/20 0.53
TDP1 Q9NUW8 5/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
PKM P14618 2/20 0.50
RECQL P46063 2/20 0.50
BLM P54132 1/20 0.50
CTDSP1 Q9GZU7 1/20 0.50
MCL1 Q07820 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6436845 0.93 KDM4E (0.61) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL6436849 0.93 KDM4E (0.61) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL6433043 0.92 MEN1 (0.66) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL6433034 0.92 MEN1 (0.66) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL6422200 0.92 KDM4E (0.62) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL6422197 0.92 KDM4E (0.62) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL6432249 0.89 KDM4E (0.61) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL6415138 0.88 KDM4E (0.60) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL6415129 0.88 KDM4E (0.60) MEN1KMT2AKDM4EALDH1A1MAPT
SCHEMBL6435516 0.85 KDM4E (0.66) MEN1KMT2AKDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds 4SC AG (DE) 2005-06-30 US disclosed
WO-2005044270-A1 OXADIAZOLOPYRAZINE DERIVATIVES AS PHARMACEUTICALLY ACTIVE COMPOUNDS 4SC AG (DE) 2005-05-19 WO disclosed
EP-1529531-A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds 4SC AG (DE) 2005-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050143382-A1 Heterocyclic compounds as pharmaceutically active compounds NR5A2, NR1H2, NR2C2 MEN1 4392/4885KMT2A 3640/4885KDM4E 3277/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.